BACKGROUND AND AIM OF THE STUDY: Aortic valve sclerosis (AVSc), the early asymptomatic stage of calcific aortic valve disease (CAVD), is characterized by a progressive thickening of the aortic cusps without obstruction of the left ventricular outflow. In spite of its high prevalence, there are no molecular markers to characterize the early stages of CAVD before it progresses to a severe, symptomatic stage of aortic valve stenosis (AVS). The study aim was to identify any correlation between circulating biomarkers and transesophageal echocardiography (TEE) evaluation. METHODS: A total of 330 patients with various degrees of CAVD was enrolled into the study. Blood was collected from each patient prior to surgery, and analyzed using ELISA kits following the manufacturers' instructions. RESULTS: Significantly higher plasma osteopontin (OPN) levels were observed in AVSc patients (72.7 +/- 1.8 ng/ml; p < 0.001) and AVS patients (64.3 +/- 5.1 ng/ml; p < 0.001) when compared to controls (30.3 +/- 1.8 ng/ml). Parathyroid hormone (PTH) levels in AVSc and AVS patients (164.1 +/- 16.5 and 134.3 +/- 14.6 pg/ml; p < 0.001 and p = 0.04, respectively) were also significantly higher than in controls (61.8 +/- 4.92 pg/ml). Upon further analysis, plasma levels of OPN (p < 0.001) and PTH (p < 0.001) were found to be significantly higher in asymptomatic AVSc patients, even before calcium deposition was detected on TEE evaluation. Fetuin-A levels were lower at all stages of CAVD when compared to controls (p < 0.001 and p < or = 0.05, respectively), but were comparable among the patient groups. NT-proBNP levels were significantly higher in AVS patients than in controls (p < or = 0.01). CONCLUSION: Serum levels of OPN, PTH, and fetuin-A showed a significant association with different stages of CAVD, with variations in their levels occurring before calcium nodules are visualized during TEE evaluation. The study results may help not only to provide a better understanding of the progression of CAVD but also to develop new tools that can be used to stage these patients.
BACKGROUND AND AIM OF THE STUDY: Aortic valve sclerosis (AVSc), the early asymptomatic stage of calcific aortic valve disease (CAVD), is characterized by a progressive thickening of the aortic cusps without obstruction of the left ventricular outflow. In spite of its high prevalence, there are no molecular markers to characterize the early stages of CAVD before it progresses to a severe, symptomatic stage of aortic valve stenosis (AVS). The study aim was to identify any correlation between circulating biomarkers and transesophageal echocardiography (TEE) evaluation. METHODS: A total of 330 patients with various degrees of CAVD was enrolled into the study. Blood was collected from each patient prior to surgery, and analyzed using ELISA kits following the manufacturers' instructions. RESULTS: Significantly higher plasma osteopontin (OPN) levels were observed in AVSc patients (72.7 +/- 1.8 ng/ml; p < 0.001) and AVS patients (64.3 +/- 5.1 ng/ml; p < 0.001) when compared to controls (30.3 +/- 1.8 ng/ml). Parathyroid hormone (PTH) levels in AVSc and AVS patients (164.1 +/- 16.5 and 134.3 +/- 14.6 pg/ml; p < 0.001 and p = 0.04, respectively) were also significantly higher than in controls (61.8 +/- 4.92 pg/ml). Upon further analysis, plasma levels of OPN (p < 0.001) and PTH (p < 0.001) were found to be significantly higher in asymptomatic AVSc patients, even before calcium deposition was detected on TEE evaluation. Fetuin-A levels were lower at all stages of CAVD when compared to controls (p < 0.001 and p < or = 0.05, respectively), but were comparable among the patient groups. NT-proBNP levels were significantly higher in AVS patients than in controls (p < or = 0.01). CONCLUSION: Serum levels of OPN, PTH, and fetuin-A showed a significant association with different stages of CAVD, with variations in their levels occurring before calcium nodules are visualized during TEE evaluation. The study results may help not only to provide a better understanding of the progression of CAVD but also to develop new tools that can be used to stage these patients.
Authors: Helmut Baumgartner; Judy Hung; Javier Bermejo; John B Chambers; Arturo Evangelista; Brian P Griffin; Bernard Iung; Catherine M Otto; Patricia A Pellikka; Miguel Quiñones Journal: J Am Soc Echocardiogr Date: 2009-01 Impact factor: 5.251
Authors: Ralf Koos; Vincent Brandenburg; Andreas Horst Mahnken; Georg Mühlenbruch; Sven Stanzel; Rolf W Günther; Jürgen Floege; Willy Jahnen-Dechent; Malte Kelm; Harald Peter Kühl Journal: Eur Heart J Date: 2009-05-08 Impact factor: 29.983
Authors: Aeron Small; Daniel Kiss; Jay Giri; Saif Anwaruddin; Hasan Siddiqi; Marie Guerraty; Julio A Chirinos; Giovanni Ferrari; Daniel J Rader Journal: Arterioscler Thromb Vasc Biol Date: 2017-02-02 Impact factor: 8.311
Authors: Alexander P Kossar; Wanda Anselmo; Juan B Grau; Yichuan Liu; Aeron Small; Samuel L Carter; Lisa Salvador; Lei Zhao; Mary Ellen Cvijic; Zhuyin Li; Melissa Yarde; Nancy Rioux; Daniel J Rader; Robert J Levy; Giovanni Ferrari Journal: Physiol Genomics Date: 2020-02-24 Impact factor: 3.107
Authors: Anton G Kutikhin; Elena A Velikanova; Rinat A Mukhamadiyarov; Tatiana V Glushkova; Vadim V Borisov; Vera G Matveeva; Larisa V Antonova; Dmitriy E Filip'ev; Alexey S Golovkin; Daria K Shishkova; Andrey Yu Burago; Alexey V Frolov; Viktor Yu Dolgov; Olga S Efimova; Anna N Popova; Valentina Yu Malysheva; Alexandr A Vladimirov; Sergey A Sozinov; Zinfer R Ismagilov; Dmitriy M Russakov; Alexander A Lomzov; Dmitriy V Pyshnyi; Anton K Gutakovsky; Yuriy A Zhivodkov; Evgeniy A Demidov; Sergey E Peltek; Viatcheslav F Dolganyuk; Olga O Babich; Evgeniy V Grigoriev; Elena B Brusina; Olga L Barbarash; Arseniy E Yuzhalin Journal: Sci Rep Date: 2016-06-02 Impact factor: 4.379
Authors: Laura Mourino-Alvarez; Tatiana Martin-Rojas; Cecilia Corros-Vicente; Nerea Corbacho-Alonso; Luis R Padial; Jorge Solis; María G Barderas Journal: J Clin Med Date: 2020-07-28 Impact factor: 4.241
Authors: Wanda Anselmo; Emanuela Branchetti; Juan B Grau; Gen Li; Salma Ayoub; Eric K Lai; Nancy Rioux; Artak Tovmasyan; Jacqueline H Fortier; Michael S Sacks; Ines Batinic-Haberle; Stanley L Hazen; Robert J Levy; Giovanni Ferrari Journal: J Am Heart Assoc Date: 2018-10-16 Impact factor: 5.501